Bone marrow edema syndrome (BMES), also known as transient regional osteoporosis, is a rare and poorly understood disease process. We present a case of an elderly patient with the BMES who had a relapsing and remitting course complicated by a hip fracture which presented the unique and a previously unreported opportunity to examine the bony architecture pathologically. The patient responded well to calcitonin and bisphosphonate therapy after surgical repair of his fracture.This case highlights an underappreciated potential complication of BMES. Though not previously reported in the literature, BMES may be associated with active osteoporotic changes, with an infrequent risk of fracture that may be amenable to potential therapeutic interventions. Pathologically, BMES may represent a spectrum of disease consisting of an osteoclast-rich phase (transient regional osteoporosis phase) predisposing to fracture in addition to the more indolent osteoclast-poor phase with bone marrow edema more commonly associated with the disease. We hypothesize that it is the osteoclastic-rich phase which may benefit from early introduction of weight bearing activities, calcitonin, bisphosphonates, or parathyroid hormone. For example, bisphosphonates reduce bone resorption directly. Indirectly, bisphosphonates may also increase osteoblast differentiation and number and thus improve bone quality, an added benefit in the treatment of bone involved in the BMES, whether in the osteoclast-rich or osteoclast-poor phase.Further study should evaluate this osteoclastic-rich phase, which may be a transient pathologic phenomenon and which has not been described previously. Transient regional osteoporosis, therefore, may represent one point in the spectrum of the BMES. Hence, we would argue that BMES is a more accurate name for the full spectrum of this disease entity.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/01.rhu.0000141509.18395.3c | DOI Listing |
Background: A 73-year-old female with a 3 year history of Alzheimer's disease was treated within the protocol of The Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study (ACIST), an IRB approved clinical study registered with clinicaltrials.gov NCT03724136.
Method: The procedure consists of bone marrow aspiration, cell separation using an FDA cleared class 2 device, and intravenous and intranasal administration of the stem cell fraction.
Acta Chir Orthop Traumatol Cech
January 2025
Ortopedická klinika, Fakultní nemocnice Hradec Králové.
Purpose Of The Study: The preclinical study aimed to compare the healing of segmental bone defects treated with biodegradable hyaluronic acid and tricalcium phosphate-based hydrogel with the established autologous spongioplasty. Another aim was to evaluate the hydrogel as a scaffold for osteoinductive growth factor of bone morphogenetic protein-2 (BMP-2) and stem cells.
Material And Methods: The study was conducted in an in vivo animal model.
Haematologica
January 2025
Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa.
Not available.
View Article and Find Full Text PDFScand J Immunol
January 2025
Department of Pediatric Hematology Oncology & Bone Marrow Transplantation Unit, University of Health Sciences Ankara Bilkent City Hospital, Ankara, Turkey.
This study retrospectively analyzed the outcomes of 61 pediatric patients with inborn errors of immunity (IEI) who underwent hematopoietic stem cell transplantation (HSCT) between 2011 and 2023. Patients were categorized into primary immunodeficiency disorders (PIDD), primary immune dysregulation disorders (PIRD), and congenital defects of phagocyte number or function (CDP). Median ages at diagnosis and HSCT were 9 and 30 months, respectively.
View Article and Find Full Text PDFCancer Med
January 2025
Department for Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Background: The histologic classification of rhabdomyosarcoma (RMS) as alveolar (aRMS) or embryonal (eRMS) is of prognostic importance, with the aRMS being associated with a worse outcome. Specific gene fusions (PAX3/7::FOXO1) found in the majority of aRMS have been recognized as markers associated with poor prognosis and are included in current risk stratification instead of histologic subtypes in localized disease. In metastatic disease, the independent prognostic significance of fusion status has not been definitively established.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!